An die Mitglieder der Arbeitsgemeinschaft Dermatologische Forschung (ADF)

Programm der AG Experimentelle Dermato-Onkologie 2015

Donnerstag, den 5. März, 9:30 bis 12:30 Uhr im Hörsaal 1, Gebäude N25,
Universität Ulm, Uni-Ost, Albert-Einstein-Allee 11, 89081 Ulm

9:30 Begrüßung

Prof. Dr. Thomas Tüting, Bonn

9:40 New lessons from mouse models about the pathogenesis of human melanoma

J. Landsberg, Bonn

10:10 The BRAF inhibitor LGX818 (encorafenib) induces endoplasmic reticulum stress and sensitizes NRAS-mutant melanoma cells to the MEK inhibitor binimetinib

H. Niessner, Tübingen/Essen/Dresden

10:30 The role of beta-catenin in the therapy resistance of malignant melanoma to BRAF inhibitors

E. Makino, Tübingen/Dresden

10:50 Kurze Pause

11:20 Y-box binding protein 1 – an emerging target to overcome vemurafenib resistance in malignant melanoma?

C. Kosnopfel, Tübingen

11:40 Inhibition of oncogenic signalling increases the efficacy of adoptive cell transfer (ACT) immunotherapy

N. Glodde, Bonn

12:00 S100A8/A9, HMGB1, and soluble forms of their receptor RAGE as novel prognostic and predictive markers in metastatic melanoma

C. Gebhardt, Mannheim/Heidelberg

12:20 Abschließende Diskussion

Prof. Dr. Thomas Tüting